Growth opportunities abound for auto-injectors amid patient-centric healthcare transition, experts tell CPHI webinar
Tremendous growth opportunities exist for auto-injectors as their value is increasingly being recognised across several therapy areas, experts have told a recent CPHI webinar, sponsored by Stevanato Group.
“Auto-injectors have grown at a CAGR of 17% over the last five years and diabetes is the largest value contributor; the injectables segment is almost completely saturated with auto-injectors providing significant benefits to patients with easy-to-use dosing mechanisms and safe handling,” Yasemin Karanis, Consultant, Thought Leadership, IQVIA, told the webinar audience, adding that further innovation in this segment aims to be more patient-centric by looking into digital and connected devices.
“The emergence of auto-injectors in the auto-immune market however is more novel and has a higher growth rate in the trend to create better patient experiences by again delivering self-administration options,” she said.
Presenting a case study on Stevanato’s Maverick, Adam Stops, Drug Delivery Systems Product Manager at Stevanato Group explained that the emergency use auto-injector is the result of a successful partnership with Duoject Medical Systems.
“We have partnered with Duoject to provide a market-leading device for our customers in the emergency use space. Along with Novocol, Duoject’s parent company, if requested, we can provide end-to-end services: the device, device manufacturing, fill/finish, and final device assembly. This is truly an end-to-end solution,” he said.
Also within the presentation, Dan MacDonald, VP Engineering, Duoject Medical Systems, provided a run-through of the development steps for Maverick.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance